A Phase 2 interventional study of 64Cu-SAR-BBN in Biochemical Recurrence of Malignant Neoplasm of Prostate, sponsored by Clarity Pharmaceuticals Ltd. Completed at 8 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by Clarity Pharmaceuticals Ltd · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with prostate-specific membrane antigen (PSMA)-negative biochemical recurrence of prostate cancer following definitive therapy.
Participants with biochemical evidence of recurrence of prostate cancer (PC) were evaluated with 64Cu-SAR-BBN PET/CT (Day 0 and Day 1) and by conventional methodologies up to 180 days later (e.g., histopathology/biopsy, conventional imaging, prostate specific antigen [PSA] reduction post focal salvage therapy or radiotherapy with no concomitant androgen deprivation therapy). Three independent, central readers blinded to the participant number, the time of the PET/CT scan, and the results of the conventional methodologies, assessed the 64Cu-SAR-BBN PET/CT. Three separate independent readers assessed the results of the conventional methodologies.
Clarity Pharmaceuticals Ltd is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Suspected recurrence of PC based on rising PSA after definitive therapy on the basis of:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive a single administration of 200 megabecquerels (MBq) of 64Cu-SAR-BBN.
Drug: 64Cu-SAR-BBN
64Cu-SAR-BBN
Safety and Tolerability
Incidence and severity of Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events. Adverse Events were assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Time frame: Up to 7 days post injection
Participant-level Correct Detection Rate (CDR) - Day 0
The percentage of true positive (TP) participants on the Day 0 scan out of all participants with a Day 0 scan.
Time frame: Day 0 (1-4 hours) post injection
Participant-level CDR - Day 1.
The percentage of TP participants on the Day 1 scan out of all participants with a Day 1 scan.
Time frame: Day 1 (24+/-6 Hours) post injection
Region-level Positive Predictive Value (PPV) - Day 0.
The percentage of TP regions on the Day 0 scan out of all positive regions on the Day 0 scan.
Time frame: Day 0 (1-4 hours) post injection
Region-level PPV - Day 1.
The percentage of TP regions on the Day 1 scan out of all positive regions on the Day 1 scan.
Time frame: Day 1 (24 +/- 6 hours) post injection
Biodistribution of 64Cu-SAR-BBN - SUVmean - Day 0
The mean Standardized Uptake Value (SUVmean) in lesions, visceral soft tissue, bone.
Time frame: Day 0 (1-4 hours) post injection
Biodistribution of 64Cu-SAR-BBN - SUVmean - Day 1
The SUVmean in lesions, visceral soft tissue, bone.
Time frame: Day 1 (24 +/- 6 hours) post injection
Biodistribution of 64Cu-SAR-BBN - SUVmax - Day 0
The max Standardized Uptake Value (SUVmax) in lesions, visceral soft tissue and bone.
Time frame: Day 0 (1-4 hours) post injection
Biodistribution of 64Cu-SAR-BBN - SUVmax - Day 1
The SUVmax in lesions, visceral soft tissue and bone.
Time frame: Day 1 (24 +/- 6 hours) post injection
Biodistribution of 64Cu-SAR-BBN - SUVr - Day 0
Standardized Uptake Value Lesion to Background ratio (SUVr): SUVmax of the lesion divided by the SUVmean of gluteus background.
Time frame: Day 0 (1-4 hours) post injection
Biodistribution of 64Cu-SAR-BBN - SUVr - Day 1
SUVr: SUVmax of the lesion divided by the SUVmean of gluteus background.
Time frame: Day 1 (24 +/- 6 hours) post injection
Participant-level PPV
Percentage of TP participants out of all positive participants, derived separately for each timepoint and reader.
Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours) post injection
Participant-level Detection Rate (DR)
Percentage of participants with a positive 64Cu-SAR-BBN PET/CT scan out of all participants with a 64Cu-SAR-BBN PET/CT scan for each timepoint and reader.
Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours) post injection
Participant-level False Positive Rate (FPR)
Percentage of false positive (FP) participants out of all participants with a positive scan, derived separately for each timepoint and reader.
Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours) post injection
Region-level FPR
Percentage of FP regions on the Day 0 or Day 1 scan out of all positive regions, derived separately for each timepoint and reader.
Time frame: Day 0 (1-4 hours) and Day 1 (24 +/-6 hours) post injection
Participant-level Discrepant PET Negativity Rate
Percentage of participants with contradicting Day 0 and Day 1 results for whom the Reference Standard was positive.
Time frame: Day 0 (1-4 hours) and Day 1 (24 +/-6 hours) post injection
Participant-level True Negative Rate (TNR)
Percentage of true negative (TN) participants on the Day 0 or Day 1 scan out of all participants with a negative Day 0 or Day 1 scan.
Time frame: Day 0 (1-4 hours) and Day 1 (24 +/-6 hours) post injection
Region-level TNR
Percentage of TN regions on the Day 0 or Day 1 scan out of all negative regions on the Day 0 or Day 1 scan.
Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours) post injection
Dates of recruitment period: 19 Sep 2022 to 14 Nov 2023
| Milestone | 64Cu-SAR-BBN |
|---|---|
| Started | 53 |
| Completed | 43 |
| Not completed | 10 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Protocol violation | 3 |
| Withdrew: Physician decision | 1 |
| Withdrew: Non-compliance | 1 |
Incidence and severity of Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events. Adverse Events were assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
| Participants | 64Cu-SAR-BBN |
|---|---|
| Any TEAE | 8 |
| TEAE Grade 1 to 2 | 8 |
| TEAE Grade 3 | 0 |
| TEAE Grade 4 to 5 | 0 |
| TEAE Related to 64Cu-SAR-BBN | 2 |
| Serious TEAE | 0 |
| TEAE Leading to Discontinuation of Study | 0 |
| TEAE Leading to Death | 0 |
The percentage of true positive (TP) participants on the Day 0 scan out of all participants with a Day 0 scan.
| percentage of participants | 64Cu-SAR-BBN |
|---|---|
| Reader 1 | 14.9 (6.2 to 28.3) |
| Reader 2 | 14.9 (6.2 to 28.3) |
| Reader 3 | 14.9 (6.2 to 28.3) |
The percentage of TP participants on the Day 1 scan out of all participants with a Day 1 scan.
| percentage of participants | 64Cu-SAR-BBN |
|---|---|
| Reader 1 | 4.3 (0.5 to 14.5) |
| Reader 2 | 10.6 (3.5 to 23.1) |
| Reader 3 | 14.9 (6.2 to 28.3) |
The percentage of TP regions on the Day 0 scan out of all positive regions on the Day 0 scan.
| percentage of regions | 64Cu-SAR-BBN |
|---|---|
| Reader 1 | 47.1 (23.0 to 72.2) |
| Reader 2 | 22.6 (9.6 to 41.1) |
| Reader 3 | 33.3 (15.6 to 55.3) |
The percentage of TP regions on the Day 1 scan out of all positive regions on the Day 1 scan.
| percentage of regions | 64Cu-SAR-BBN |
|---|---|
| Reader 1 | 22.2 (2.8 to 60.0) |
| Reader 2 | 35.3 (14.2 to 61.7) |
| Reader 3 | 37.5 (18.8 to 59.4) |
The mean Standardized Uptake Value (SUVmean) in lesions, visceral soft tissue, bone.
| kg/L | Reader 1 | Reader 2 | Reader 3 |
|---|---|---|---|
| All Lesions | 5.470 ± 3.2058 | 3.773 ± 2.5440 | 5.671 ± 8.0303 |
| Soft Tissue Lesions | 5.699 ± 3.5380 | 4.362 ± 2.9050 | 6.427 ± 8.5057 |
| Bone Lesions | 3.703 ± NA | 2.482 ± 1.2925 | 2.353 ± 2.0118 |
The SUVmean in lesions, visceral soft tissue, bone.
| kg/L | Reader 1 | Reader 2 | Reader 3 |
|---|---|---|---|
| All Lesions | 2.586 ± 1.9814 | 1.450 ± 1.5305 | 1.179 ± 1.5309 |
| Soft Tissue Lesions | 2.586 ± 1.9814 | 1.586 ± 1.7712 | 1.652 ± 2.0244 |
| Bone Lesions | — | 2.116 ± 2.3684 | 0.772 ± 0.4263 |
The max Standardized Uptake Value (SUVmax) in lesions, visceral soft tissue and bone.
| kg/L | Reader 1 | Reader 2 | Reader 3 |
|---|---|---|---|
| All Lesions | 7.335 ± 4.0904 | 5.314 ± 3.1471 | 14.436 ± 27.7988 |
| Soft Tissue Lesions | 7.705 ± 4.7952 | 5.910 ± 3.8559 | 16.368 ± 29.7231 |
| Bone Lesions | 5.041 ± NA | 4.144 ± 1.8181 | 5.013 ± 3.6903 |
The SUVmax in lesions, visceral soft tissue and bone.
| kg/L | Reader 1 | Reader 2 | Reader 3 |
|---|---|---|---|
| All Lesions | 4.179 ± 3.3173 | 2.762 ± 3.5449 | 2.763 ± 3.2511 |
| Soft Tissue Lesions | 4.179 ± 3.3173 | 2.930 ± 4.1078 | 3.965 ± 4.5243 |
| Bone Lesions | — | 5.017 ± 6.2016 | 1.945 ± 0.8572 |
Standardized Uptake Value Lesion to Background ratio (SUVr): SUVmax of the lesion divided by the SUVmean of gluteus background.
| ratio | Reader 1 | Reader 2 | Reader 3 |
|---|---|---|---|
| Biodistribution of 64Cu-SAR-BBN - SUVr - Day 0 | 14.566 ± 8.1016 | 10.020 ± 5.1889 | 13.442 ± 17.6749 |
SUVr: SUVmax of the lesion divided by the SUVmean of gluteus background.
| ratio | Reader 1 | Reader 2 | Reader 3 |
|---|---|---|---|
| Biodistribution of 64Cu-SAR-BBN - SUVr - Day 1 | 55.957 ± 36.4771 | 40.617 ± 24.7419 | 36.254 ± 45.2321 |
Percentage of TP participants out of all positive participants, derived separately for each timepoint and reader.
| percentage of participants | Participant-level PPV - Day 0 | Participant-level PPV - Day 1 |
|---|---|---|
| Reader 1 | 58.3 (27.7 to 84.8) | 33.3 (4.3 to 77.7) |
| Reader 2 | 31.8 (13.9 to 54.9) | 38.5 (13.9 to 68.4) |
| Reader 3 | 36.8 (16.3 to 61.6) | 43.8 (19.8 to 70.1) |
Percentage of participants with a positive 64Cu-SAR-BBN PET/CT scan out of all participants with a 64Cu-SAR-BBN PET/CT scan for each timepoint and reader.
| percentage of participants | Participant-level DR - Day 0 | Participant-level DR - Day 1 |
|---|---|---|
| Reader 1 | 24.5 (13.8 to 38.3) | 17.0 (8.1 to 29.8) |
| Reader 2 | 43.4 (29.8 to 57.7) | 28.3 (16.8 to 42.3) |
| Reader 3 | 37.7 (24.8 to 52.1) | 37.7 (24.8 to 52.1) |
Percentage of false positive (FP) participants out of all participants with a positive scan, derived separately for each timepoint and reader.
| percentage of participants | Participant-level FPR - Day 0 | Participant-level FPR - Day 1 |
|---|---|---|
| Reader 1 | 41.7 (15.2 to 72.3) | 66.7 (22.3 to 95.7) |
| Reader 2 | 68.2 (45.1 to 86.1) | 61.5 (31.6 to 86.1) |
| Reader 3 | 63.2 (38.4 to 83.7) | 56.3 (29.9 to 80.2) |
Percentage of FP regions on the Day 0 or Day 1 scan out of all positive regions, derived separately for each timepoint and reader.
| percentage of regions | Region-level FPR - Day 0 | Region-level FPR - Day 1 |
|---|---|---|
| Reader 1 | 52.9 (27.8 to 77.0) | 77.8 (40.0 to 97.2) |
| Reader 2 | 77.4 (58.9 to 90.4) | 64.7 (38.3 to 85.8) |
| Reader 3 | 66.7 (44.7 to 84.4) | 62.5 (40.6 to 81.2) |
Percentage of participants with contradicting Day 0 and Day 1 results for whom the Reference Standard was positive.
| percentage of participants | 64Cu-SAR-BBN |
|---|---|
| Reader 1 | 26.3 (9.1 to 51.2) |
| Reader 2 | 15.8 (3.4 to 39.6) |
| Reader 3 | 10.5 (1.3 to 33.1) |
Percentage of true negative (TN) participants on the Day 0 or Day 1 scan out of all participants with a negative Day 0 or Day 1 scan.
| percentage of participants | Participant-level TNR - Day 0 | Participant-level TNR - Day 1 |
|---|---|---|
| Reader 1 | 82.1 (63.1 to 93.9) | 85.7 (67.3 to 96.0) |
| Reader 2 | 57.1 (39.4 to 73.7) | 77.1 (59.9 to 89.6) |
| Reader 3 | 58.6 (38.9 to 76.5) | 69.0 (49.2 to 84.7) |
Percentage of TN regions on the Day 0 or Day 1 scan out of all negative regions on the Day 0 or Day 1 scan.
| percentage of regions | Region-level TNR - Day 0 | Region-level TNR - Day 1 |
|---|---|---|
| Reader 1 | 95.8 (92.2 to 98.1) | 96.7 (93.4 to 98.7) |
| Reader 2 | 88.2 (82.9 to 92.3) | 94.6 (90.6 to 97.3) |
| Reader 3 | 92.6 (88.2 to 95.7) | 93.0 (88.8 to 96.0) |
Collected over From time of informed consent up to 7 days post injection. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 64Cu-SAR-BBN | 0/53 (0%) | 0/53 (0%) | 3/53 (5.7%) |
| Event | 64Cu-SAR-BBN |
|---|---|
| HeadacheNervous system disorders | 3/53 |
All enrolled participants who received any amount of 64Cu-SAR-BBN.
| Age, Categorical(Participants) | 64Cu-SAR-BBN |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 12 |
| >=65 years | 41 |
| Sex: Female, Male(Participants) | 64Cu-SAR-BBN |
|---|---|
| Female | 0 |
| Male | 53 |
| Ethnicity (NIH/OMB)(Participants) | 64Cu-SAR-BBN |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 46 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | 64Cu-SAR-BBN |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 48 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | 64Cu-SAR-BBN |
|---|---|
| United States | 53 |
| Baseline Prostate Specific Antigen (PSA)(ng/mL) | 64Cu-SAR-BBN |
|---|---|
| Mean | 3.3932 ± 6.13380 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2022 to primary completion in May 2024, 19 months.
Results were first posted in Nov 2025, 1 year 6 months after primary completion. A results delay was requested in Mar 2025.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sar-bbn CU-64
Clarity Pharmaceuticals Ltd